171 related articles for article (PubMed ID: 29901070)
21. Inhibitory roles of miR‑9 on papillary thyroid cancer through targeting BRAF.
Gu Y; Yang N; Yin L; Feng C; Liu T
Mol Med Rep; 2018 Jul; 18(1):965-972. PubMed ID: 29767243
[TBL] [Abstract][Full Text] [Related]
22. Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/β-catenin signaling pathway.
Zhou Z; Liu Y; Ma M; Chang L
Biomed Pharmacother; 2017 Dec; 96():98-103. PubMed ID: 28965013
[TBL] [Abstract][Full Text] [Related]
23. Long Noncoding RNA HOXA-AS2 Promotes Papillary Thyroid Cancer Progression by Regulating miR-520c-3p/S100A4 Pathway.
Xia F; Chen Y; Jiang B; Du X; Peng Y; Wang W; Huang W; Feng T; Li X
Cell Physiol Biochem; 2018; 50(5):1659-1672. PubMed ID: 30384358
[TBL] [Abstract][Full Text] [Related]
24. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
[TBL] [Abstract][Full Text] [Related]
25. ZNRF3 is downregulated in papillary thyroid carcinoma and suppresses the proliferation and invasion of papillary thyroid cancer cells.
Qiu W; Yang Z; Fan Y; Zheng Q
Tumour Biol; 2016 Sep; 37(9):12665-12672. PubMed ID: 27448298
[TBL] [Abstract][Full Text] [Related]
26. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
[TBL] [Abstract][Full Text] [Related]
27. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
28. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
Ma Y; Qin H; Cui Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
[TBL] [Abstract][Full Text] [Related]
29. A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC.
Occhi G; Barollo S; Regazzo D; Bertazza L; Galuppini F; Guzzardo V; Jaffrain-Rea ML; Vianello F; Ciato D; Ceccato F; Watutantrige-Fernando S; Bisognin A; Bortoluzzi S; Pennelli G; Boscaro M; Scaroni C; Mian C
Oncotarget; 2015 Oct; 6(31):32104-14. PubMed ID: 26392334
[TBL] [Abstract][Full Text] [Related]
30. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.
Minna E; Romeo P; Dugo M; De Cecco L; Todoerti K; Pilotti S; Perrone F; Seregni E; Agnelli L; Neri A; Greco A; Borrello MG
Oncotarget; 2016 Mar; 7(11):12731-47. PubMed ID: 26871295
[TBL] [Abstract][Full Text] [Related]
31. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S
Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
[TBL] [Abstract][Full Text] [Related]
32. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
33. Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters.
Jendrzejewski J; Liyanarachchi S; Nagy R; Senter L; Wakely PE; Thomas A; Nabhan F; He H; Li W; Sworczak K; Ringel MD; Kirschner LS; de la Chapelle A
Thyroid; 2016 Sep; 26(9):1276-84. PubMed ID: 27342578
[TBL] [Abstract][Full Text] [Related]
34. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
35. Concomitant high expression of ERα36, GRP78 and GRP94 is associated with aggressive papillary thyroid cancer behavior.
Dai YJ; Qiu YB; Jiang R; Xu M; Liao LY; Chen GG; Liu ZM
Cell Oncol (Dordr); 2018 Jun; 41(3):269-282. PubMed ID: 29368272
[TBL] [Abstract][Full Text] [Related]
36. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
37. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
38. Tumor promoting effects of glucagon receptor: a promising biomarker of papillary thyroid carcinoma via regulating EMT and P38/ERK pathways.
Jiang HC; Chen XR; Sun HF; Nie YW
Hum Cell; 2020 Jan; 33(1):175-184. PubMed ID: 31782107
[TBL] [Abstract][Full Text] [Related]
39. Genomic evidence of reactive oxygen species elevation in papillary thyroid carcinoma with Hashimoto thyroiditis.
Yi JW; Park JY; Sung JY; Kwak SH; Yu J; Chang JH; Kim JH; Ha SY; Paik EK; Lee WS; Kim SJ; Lee KE; Kim JH
Endocr J; 2015; 62(10):857-77. PubMed ID: 26211532
[TBL] [Abstract][Full Text] [Related]
40. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
